The Storm Therapeutics/Cambridge METTL3 RNA methyltransferase inhibitor, STM-2457, is a first-in-class catalytic inhibitor of the METTL3 RNA modifying enzyme. DNA-methyltransferase and other epigenetic targets such as HDACs have been explored for their potential roles in cancer and other diseases, and this compound brings RNA modifying [...]
< 1 minute read
Sep. 18, 2021
STM-2457: A METTL3 RNA Modifying Enzyme Inhibitor
STM-2457
METTL3 RNA modifying enzyme inhibitor efficacy in AML PDX model (50 mg/kg IP) from 250k compound HTS Nature, Apr. 26, 2021 Storm Therapeutics / University of Cambridge